Comparable outcome of liver transplantation with Histidine-Tryptophan-Ketoglutarate vs. University of Wisconsin preservation solution: a retrospective observational double-center trial
Open Access
- 28 September 2014
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 14 (1) , 169
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Avoid more organ transplant scandalsNature, 2013
- Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany - limitations of the ‘sickest first’-conceptTransplant International, 2010
- Histidine–Tryptophan–Ketoglutarate (HTK) Is Associated with Reduced Graft Survival in Deceased Donor Livers, Especially Those Donated After Cardiac DeathAmerican Journal of Transplantation, 2009
- Cost Prediction in Liver Transplantation Using Pretransplant Donor and Recipient CharacteristicsTransplantation, 2008
- Liver preservation: is there anything new yet?Current Opinion in Organ Transplantation, 2008
- Biliary complications following liver transplantation in the model for end-stage liver disease era: Effect of donor, recipient, and technical factorsLiver Transplantation, 2008
- Histidine-tryptophan-ketoglutarate solution vs. University of Wisconsin solution for liver transplantation: A systematic reviewLiver Transplantation, 2007
- Comparison of histidine-tryptophan-ketoglutarate solution (HTK) and University of Wisconsin solution (UW) in adult liver transplantationLiver Transplantation, 2006
- Applicability of histidine-tryptophan-ketoglutarate solution in right lobe adult-to-adult live donor liver transplantationLiver Transplantation, 2004
- Comparison of histidine-tryptophan-ketoglutarate (HTK) solution versus University of Wisconsin (UW) solution for organ preservation in human liver transplantationTransplant International, 1994